<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38464">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844622</url>
  </required_header>
  <id_info>
    <org_study_id>07-39-H-08</org_study_id>
    <nct_id>NCT01844622</nct_id>
  </id_info>
  <brief_title>Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying</brief_title>
  <acronym>No</acronym>
  <official_title>Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mt. Sinai Medical Center, Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mt. Sinai Medical Center, Miami</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to treat patients with on-going slow stomach
      emptying(gastroesophageal reflux disease), who have failed to respond to standard therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study on the effectiveness of domperidone, which increases movement through the
      digestive system for relief of symptoms, in patients who have delayed gastric solid-phase
      emptying
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Clinical Applications of Domperidone in Patients with Refractory Gastroesophageal Reflux Disease (GERD)or Delayed Gastric Solid-Phase Emptying</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>GERD or Delayed Gastric Emptying</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Digestive System Disease</condition>
  <arm_group>
    <arm_group_label>Domperidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.</description>
    <arm_group_label>Domperidone</arm_group_label>
    <other_name>Motilium</other_name>
    <other_name>Motillium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent esophagitis

          -  Heartburn

          -  Nausea

          -  Vomiting

          -  Severe dyspepsia

          -  Severe chronic constipation

        Exclusion Criteria:

          -  History of, or current arrhythmias including ventricular tachycardia,   - Ventricular
             fibrillation and Torsade des Pointes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie S. Barkin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie S Barkin, M.D.</last_name>
    <phone>305-674-2240</phone>
    <email>jamiebarkin@msmc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center, Division of Gastroenterology</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie S Barkin, M.D.</last_name>
      <phone>305-674-2240</phone>
      <email>jamiebarkin@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Jamie S Barkin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center, Division of Gastroenterology</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie S. Barkin, M.D.</last_name>
      <phone>305-674-2240</phone>
      <email>jamiebarkin@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Jamie S Barkin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology, Mt. Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie S Barkin, M.D.</last_name>
      <phone>305-674-2240</phone>
      <email>jamiebarkin@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Jamie S. Barkin, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 8, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mt. Sinai Medical Center, Miami</investigator_affiliation>
    <investigator_full_name>Jamie S. Barkin, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine, U of Miami and Chief, Div  of GI, Mt. Sinai Med. Ctr</investigator_title>
  </responsible_party>
  <keyword>Digestive System Diseases Disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
